The initial objective of this study was to identify biomarkers in the population of circulating cytotoxic cells in healthy donors that may be linked to their cytotoxic activity, namely ADCC, in an experimental system where a target tumor cell-line express strongly HER2 and in the presence of anti-HER2 antibody trastuzumab. This evidence concerns the gene ERBB2 and neoplasm.